Entasis Therapeutics Holdings Inc. (ETTX): Price and Financial Metrics
ETTX Price/Volume Stats
|Current price||$2.19||52-week high||$3.88|
|Prev. close||$2.20||52-week low||$1.40|
|Day high||$2.20||Avg. volume||239,104|
|50-day MA||$2.06||Dividend yield||N/A|
|200-day MA||$2.23||Market Cap||104.80M|
ETTX Stock Price Chart Interactive Chart >
Entasis Therapeutics Holdings Inc. (ETTX) Company Bio
Entasis Therapeutics Inc. discovers and develops antibacterials to fight diseases caused by multidrug-resistant bacteria. It offers ETX2514, a broad-spectrum and potent inhibitor of class A, C, and D beta-lactamases that has activity against Acinetobacter baumannii, a gram-negative bacterium that causes severe infections, which are associated with high mortality; ETX0914, a novel oral antibiotic for the treatment of uncomplicated gonorrhea; and a drug discovery platform that focuses on developing novel antibacterials targeting serious gram-negative infections, such as pneumonia, infections of the blood, urinary tract infections, and infections following surgery. Entasis Therapeutics Inc. has strategic development collaboration with Zai Lab Limited. The company was founded in 2015 and is based in Waltham, Massachusetts. Entasis Therapeutics Inc. operates as a subsidiary of AstraZeneca PLC.
ETTX Latest News Stream
|Loading, please wait...|
ETTX Latest Social Stream
View Full ETTX Social Stream
Latest ETTX News From Around the Web
Below are the latest news stories about ENTASIS THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate ETTX as an investment opportunity.
Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual Conference
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced multiple presentations at the American Society for Microbiology (ASM) annual Microbe conference, taking place June 9-13, 2022, in Washington, DC. Entasis is presenting data on sulbactam-durlobactam (SUL-DUR), an investigational drug in development for the treat
Regulatory updates and acquisition news from Entasis (ETTX) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
ENTASIS ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of ETTX and Encourages Investors to Contact the Firm
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Innoviva, Inc. (NASDAQ: INVA).
Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.
Entasis Therapeutics, an antibiotics developer that spun out of AstraZeneca plc in 2015, has been acquired by its majority shareholder, California's Innoviva Inc.
ETTX Price Returns